Gut check: Newest microbiome startup concentrates on autism, Parkinson’s disease
What kind of relationship exists between the gut microbiome and diseases of the brain? A new startup called Axial Biotherapeutics has set out to find some answers, with $19.15 million in venture backing.
Caltech professor Sarkis Mazmanian has provided much of the inspiration for the biotech. His lab has published research on animal studies that established a link between the population of tiny microbes in your body and the course of autism spectrum disorders. And the biotech plans to take that work into the clinic in search of new drugs that can treat some terrible, and difficult-to-treat, diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
